Clinical Trial - NCT03148418

A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Recruiting

Sponsor: Hoffmann-La Roche

Collaborators:

Information provided by (Responsible party): Sponsor

ClinicalTrials.gov Identifier: NCT03148418

Protocol Info

Short Description: A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Long Description: An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffman-LaRoche LTD Sponsored Atezolizumab Study
MGH Status: Open
Sponsor: Hoffman-LaRoche
Disease Program: Breast

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.
Condition Title Intervention Phase
Cancer Atezolizumab Phase 3
Study Type Interventional
Official Title An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study

Primary Outcome Measures

Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s) [Time Frame: Day 1 up to maximum 10 years] [Designated as safety issue: ]


Secondary Outcome Measures

Percentage of Participants With Serious Adverse Events (SAEs) by Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [Time Frame: Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)] [Designated as safety issue: ]

Percentage of Participants With Adverse Events of Special Interest by Severity Determined According to NCI CTCAE Version 4.0 [Time Frame: Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)] [Designated as safety issue: ]

Time from Randomization or Treatment Initiation to Death due to any Cause [Time Frame: Day 1 (as indicated in parent study protocol) until death due to any cause (up to maximum 10 years)] [Designated as safety issue: ]

Estimated Enrollment: 546
Study Start Date: September 2017
Estimated Study Completion Date: August 2027
Estimated Primary Completion Date: August 2027
Arms Assigned Interventions

Experimental:Atezolizumab

Participants will continue to receive atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
Drug:Atezolizumab
Atezolizumab will be administered as monotherapy or combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study). Dosing regimen will be in accordance with the parent study and local prescribing information.

Eligibility

Ages Eligible for Study: N/A

Genders Eligible for Study: All

Accepts Healthly Volunteers: No

Inclusion Criteria:

Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study:

  • Eligible for continuing or crossing over to atezolizumab-based therapy at the time of the parent-study closure as per the parent study or eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the parent-study closure as per the parent study
  • First dose of study treatment in the extension study will be received within 7 days of the treatment interruption window allowed by the parent study
  • Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of parent-study closure as assessed by the investigator
  • Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential

Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:

  • Discontinuation of atezolizumab-based therapy in parent study and in survival follow up at the time of parent study closure, or eligible for continuing or crossing over to atezolizumab-based therapy as per the parent protocol and have access to commercially available atezolizumab (Tecentriq) outside this extension study at the time of the parent-study closure

Exclusion Criteria:

Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study:

  • Meet of any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in the extension study
  • Study treatment is commercially marketed in the patient's country for the patient specific disease and is accessible to the patient
  • Time between the last dose of treatment received in parent study and first dose in extension study is longer than the interruption period (± 7 days) allowed in the parent study
  • Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in the extension study
  • Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study (if applicable)
  • Any unresolved or irreversible toxicities during the parent study that required permanent discontinuation of study treatment, in accordance to the parent study or local prescribing information
  • Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to (<=) 1 from the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study
  • Any serious uncontrolled concomitant disease that would contraindicate the use of study treatment at the time of the extension study or that would place the participant at high risk for treatment-related complications
  • Concurrent participation in any therapeutic clinical trial (other than the parent study)

Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:

  • Discontinuation of comparator in parent study and in survival follow-up at the time of parent study closure

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT03148418

Locations

  • United States, Arizona
    • HonorHealth Research Institute - Bisgrove Scottsdale, Arizona, United States, 85258
  • United States, California
    • UCLA Los Angeles, California, United States, 90024
    • Angeles Clinic & Rsch Inst Los Angeles, California, United States, 90025
    • Kaiser Permanente - San Diego (Zion Ave) San Marcos, California, United States, 92078
    • Kaiser Permanente - Vallejo Vallejo, California, United States, 94589
  • United States, Colorado
    • University Of Colorado Aurora, Colorado, United States, 80045
    • Rocky Mountain Cancer Ctr - Denver (Williams) Denver, Colorado, United States, 80218
  • United States, Connecticut
    • Smilow Cancer Hospital at Yale New Haven New Haven, Connecticut, United States, 06510
  • United States, District of Columbia
    • Georgetown University Medical Center Lombardi Cancer Center Washington, District of Columbia, United States, 20007
  • United States, Florida
    • Florida Cancer Specialists - Fort Myers (Broadway) Fort Myers, Florida, United States, 33916
    • Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States, 34952
    • Florida Cancer Specialists. Saint Petersburg, Florida, United States, 33705
    • H. Lee Moffitt Cancer Center and Research Inst. Tampa, Florida, United States, 33612
  • United States, Georgia
    • Northwest Georgia Oncology Centers P.C. Carrollton, Georgia, United States, 30117
  • United States, Illinois
    • Northwestern University; Robert H. Lurie Comp Can Ctr Chicago, Illinois, United States, 60611
    • University Of Chicago Medical Center; Section Of Hematology/Oncology Chicago, Illinois, United States, 60637
    • Ingalls Memorial Hospital Harvey, Illinois, United States, 60426
    • Illinois Cancer Care Peoria, Illinois, United States, 61615
    • Southern Illinois University, School of Medicine, Simmons Cancer Institute Springfield, Illinois, United States, 62702
  • United States, Kentucky
    • Lahey Clinic Med Ctr Lexington, Kentucky, United States, 02421
  • United States, Maine
    • New England Cancer Specialists Scarborough, Maine, United States, 04074
  • United States, Maryland
    • Johns Hopkins Univ Med Center Baltimore, Maryland, United States, 21231
  • United States, Massachusetts
    • Massachusetts General Hospital. Boston, Massachusetts, United States, 02114
    • Dana Farber Cancer Inst. ; Dept. of Medical Oncology Boston, Massachusetts, United States, 02115
    • Southcoast Health System Fairhaven, Massachusetts, United States, 02719
  • United States, Michigan
    • Karmanos Cancer Institute Detroit, Michigan, United States, 48201
  • United States, Minnesota
    • US Oncology Research at Minnesota Oncology Minneapolis, Minnesota, United States, 55404
  • United States, Missouri
    • Washington University School of Medicine Saint Louis, Missouri, United States, 63110
  • United States, Nebraska
    • Southeast Nebraska Hematology and Oncology Consultants, P.C. Lincoln, Nebraska, United States, 68510
  • United States, Nevada
    • Comprehensive Cancer Centers of Nevada - Eastern Avenue Las Vegas, Nevada, United States, 89169
    • Va Sierra Nevada Health Care System Reno, Nevada, United States, 89502
  • United States, New Jersey
    • Summit Medical Center Florham Park, New Jersey, United States, 07932
  • United States, New York
    • New York Oncology Hematology, P.C. Albany, New York, United States, 12206
    • Memorial Sloan-Kettering Cancer Center Commack, New York, United States, 11725
    • Beth Israel Medical Center; Division of Digestive Diseases New York, New York, United States, 10003
  • United States, North Carolina
    • Carolina BioOncology Institute, PLCC Huntersville, North Carolina, United States, 28078
  • United States, Ohio
    • Oncology Hematology Care Inc Cincinnati, Ohio, United States, 45242
    • Cleveland Clinic Cleveland, Ohio, United States, 44106
    • Oncology Hematology Care, Inc. Hamilton, Ohio, United States, 45103
  • United States, Oregon
    • Oncology Associates of Oregon, P.C Eugene, Oregon, United States, 97401
    • Northwest Cancer Specialists - Portland (N Broadway) Portland, Oregon, United States, 97227
  • United States, Pennsylvania
    • St. Luke's Cancer Care Associates Bethlehem, Pennsylvania, United States, 18015
    • Penn State Hershey Cancer Institute Hershey, Pennsylvania, United States, 17033
  • United States, Rhode Island
    • Rhode Island Hospital Providence, Rhode Island, United States, 02903
  • United States, South Carolina
    • Greenville Health System; Cancer Center Greenville, South Carolina, United States, 29605-4292
  • United States, Tennessee
    • Tennessee Cancer Specialists Knoxville, Tennessee, United States, 37920
    • Sarah Cannon Res Inst; TN Onc Nashville, Tennessee, United States, 37203
    • Vanderbilt Univ Medical Ctr Nashville, Tennessee, United States, 37203
  • United States, Texas
    • Texas Oncology-Baylor Sammons Cancer Center Dallas, Texas, United States, 75246
    • Tyler Cancer Center Fort Worth, Texas, United States, 76177
  • United States, Virginia
    • Virginia Oncology Associates - Lake Wright Cancer Center Norfolk, Virginia, United States, 23502
    • Blue Ridge Cancer Care Roanoke, Virginia, United States, 24014
  • United States, Washington
    • University of Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98195
  • Australia, Queensland
    • Princess AleXandra Hospital; Department of Medical Oncology Woolloongabba, Queensland, Australia, 4102
  • Austria,
    • Klinikum Wels-Grieskirchen; Lungenabt. Wels, , Austria, 4600
  • Belgium,
    • GHdC Site Notre Dame Charleroi, , Belgium, 6000
    • Clinique Ste-Elisabeth Namur, , Belgium, 5000
    • Sint Augustinus Wilrijk Wilrijk, , Belgium, 2610
  • Bulgaria,
    • Multiprofile Hospital for Active Treatment Serdika EOOD; Medical Oncology Department Sofia, , Bulgaria, 1303
  • Canada, Ontario
    • Royal Victoria Hospital Barrie, Ontario, Canada, L4M 6M2
    • William Osler Health Centre Etobicoke, Ontario, Canada, M9V 1R8
    • Lakeridge Health Corporation-Oshawa; Oncology clinic Oshawa, Ontario, Canada, L1G 2B9
    • Sunnybrook Odette Cancer Centre; Clinical Trials Toronto, Ontario, Canada, M4N 3M5
    • Princess Margaret Hospital, Medical Oncology & Haematology Toronto, Ontario, Canada, M5G 2M9
  • Canada, Quebec
    • Cite de La Sante de Laval; Hemato-Oncologie Laval, Quebec, Canada, H7M 3L9
    • Hôpital Maisonneuve-Rosemont installation CIUSSS-de-l'Est-de-l'Île-de-Montréal Montreal, Quebec, Canada, H1T 2M4
    • McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology Montreal, Quebec, Canada, H3T 1E2
  • Chile,
    • Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas Recoleta, , Chile, 8420383
  • Czechia,
    • Masarykuv onkologicky ustav Brno, , Czechia, 656 53
    • Fakultni nemocnice Olomouc; Onkologicka klinika Olomouc, , Czechia, 779 00
  • France,
    • Hopital Jean Minjoz; Pneumologie Besancon, , France, 25030
    • Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie Grenoble, , France, 38043
    • Centre Leon Berard; Departement Oncologie Medicale Lyon, , France, 69373
    • Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique Marseille, , France, 13915
    • Centre René Gauducheau - cancer Nantes - Atlantique; Service Oncologie Médicale Nantes, , France, 44805
    • Centre Antoine Lacassagne, Centre de Lutte Contre le Cancer (CLCC) de Nice Nice, , France, 06189
    • Hopital Saint Louis; Oncologie Medicale Paris, , France, 75475
    • GH Paris Saint Joseph; Pneumologie Paris, , France, 75674
    • Hopital Tenon;Pneumologie Paris, , France, 75970
    • CHU Bordeaux Pessac, , France, 33604
    • Centre Hospitalier Lyon Sud Pierre Benite, , France, 69495
    • Centre Medico-Chirurgical Foch; Service de Pneumologie Suresnes, , France, 92151
    • CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique Toulouse cedex 9, , France, 31100
    • Institut Gustave Roussy; Sitep VILLEJUIF Cedex, , France, 94805
  • Georgia,
    • Research institute for Clinical Medicine Tbilisi, , Georgia, 0112
  • Germany,
    • Klinikum d.Universität München Campus Großhadern München, , Germany, 81377
  • Hungary,
    • Orszagos Koranyi TBC es Pulmonologiai Intezet Budapest, , Hungary, 1121
    • Semmelweis Egyetem X; Pulmonologiai Klinika Budapest, , Hungary, 1125
    • Tudogyogyintezet Torokbalint Torokbalint, , Hungary, 2045
  • Italy, Campania
    • Azienda Ospedaliera A. Cardarelli; Dip. Oncopneumoematologico Napoli, Campania, Italy, 80131
  • Italy, Emilia-Romagna
    • A.O. Universitaria Policlinico Di Modena; Oncologia Modena, Emilia-Romagna, Italy, 41100
  • Italy, Friuli-Venezia Giulia
    • Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica Aviano, Friuli-Venezia Giulia, Italy, 33081
  • Italy, Lombardia
    • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1 Milano, Lombardia, Italy, 20133
    • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2 Milano, Lombardia, Italy, 20133
    • Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica Milano, Lombardia, Italy, 20141
    • ASST DI MONZA; Oncologia Medica Monza, Lombardia, Italy, 20900
  • Italy, Piemonte
    • Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico Orbassano, Piemonte, Italy, 10043
  • Italy, Toscana
    • Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia Arezzo, Toscana, Italy, 52100
    • A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii Pisa, Toscana, Italy, 56124
    • A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii Pisa, Toscana, Italy, 56124
    • Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica Siena, Toscana, Italy, 53100
  • Italy, Veneto
    • IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II Padova, Veneto, Italy, 35128
  • Japan,
    • Iwate Medical University Hospital; Urology Iwate, , Japan, 020-8505
    • Okayama University Hospital; Respiratory and Allergy Medicine Okayama, , Japan, 700-8558
    • Toranomon Hospital; Medical Oncology Tokyo, , Japan, 105-8470
    • The Cancer Institute Hospital of JFCR, Respiratory Medicine Tokyo, , Japan, 135-8550
  • Korea, Republic of,
    • National Cancer Center Gyeonggi-do, , Korea, Republic of, 10408
    • Chonnam National University Hwasun Hospital Jeollanam-do, , Korea, Republic of, 58128
    • Samsung Medical Center Seoul, , Korea, Republic of, 6351
  • Lithuania,
    • Institute of Oncology Vilnius University Vilnius, , Lithuania, 08660
  • Netherlands,
    • NKI/AvL Amsterdam, , Netherlands, 1066 CX
  • New Zealand,
    • Auckland city hospital; Auckland Regional Cancer Centre and Blood Service Auckland, , New Zealand, 1023
  • Poland,
    • Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii Gdańsk, , Poland, 80-952
    • Oddział Onkologii Klinicznej i Chemioterapii Szpitala ELBLĄSKA Warszawa, , Poland, 01-748
    • Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie; Klinika Nowotworow Pluca i Klatki Piersiowej Warszawa, , Poland, 02-781
  • Portugal,
    • Hospital de Santa Maria; Servico de Oncologia Medica Lisboa, , Portugal, 1649-035
  • Romania,
    • Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, , Romania, 400015
    • Institut Oncologic Ion Chiricuta; Departament Radioterapie Cluj-napoca, , Romania, 400015
    • ONCOMED - Medical Centre Timisoara, , Romania, 300239
  • Russian Federation, Niznij Novgorod
    • GBUZ Nizhegorodskay Region: Clinical Diagnostic Center Nizhni Novgorod, Niznij Novgorod, Russian Federation, 603001
  • Serbia,
    • Clinic for Pulmonology, Clinical Center of Serbia Belgrade, , Serbia, 11000
  • Singapore,
    • National University Hospital; National University Cancer Institute, Singapore (NCIS) Singapore, , Singapore, 119228
    • National Cancer Centre; Medical Oncology Singapore, , Singapore, 169610
  • Slovakia,
    • Narodny onkologicky ustav Bratislava, , Slovakia, 833 10
  • Slovenia,
    • Institute of Oncology Ljubljana Ljubljana, , Slovenia, 1000
    • Institute of Oncology Ljubljana Ljubljana, , Slovenia, 1000
  • Spain, Barcelona
    • Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia Badalona, Barcelona, Spain, 08916
  • Spain, Cordoba
    • Hospital Universitario Reina Sofia; Servicio de Oncologia Córdoba, Cordoba, Spain, 14004
  • Spain, LAS Palmas
    • Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia Las Palmas de Gran Canaria, LAS Palmas, Spain, 35016
  • Spain, Navarra
    • Clinica Universitaria de Navarra; Servicio de Oncologia Pamplona, Navarra, Spain, 31008
  • Spain,
    • Hospital Univ Vall d'Hebron; Servicio de Oncologia Barcelona, , Spain, 08035
    • Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department Barcelona, , Spain, 08036
    • Institut Catala d Oncologia Hospital Duran i Reynals Barcelona, , Spain, 08908
    • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología La Coruña, , Spain, 15006
    • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia Madrid, , Spain, 28007
    • Hospital Ramon y Cajal; Servicio de Oncologia Madrid, , Spain, 28034
    • Hospital Universitario Clínico San Carlos; Servicio de Oncologia Madrid, , Spain, 28040
    • Hospital Universitario 12 de Octubre; Servicio de Oncologia Madrid, , Spain, 28041
    • Hospital Universitario La Paz; Servicio de Oncologia Madrid, , Spain, 28046
    • Hospital Regional Universitario Carlos Haya; Servicio de Oncologia Malaga, , Spain, 29010
    • Hospital Universitario Virgen del Rocio; Servicio de Oncologia Sevilla, , Spain, 41013
    • Hospital General Universitario de Valencia; Servicio de oncologia Valencia, , Spain, 41014
  • Switzerland,
    • CHUV; Departement d'Oncologie Lausanne, , Switzerland, 1011
  • Taiwan,
    • China Medical University Hospital; Urology Taichung, , Taiwan, 40447
    • National Taiwan Uni Hospital; Dept of Oncology Taipei, , Taiwan, 100
  • Thailand,
    • Chulalongkorn Hospital; Medical Oncology Bangkok, , Thailand, 10330
    • Ramathibodi Hospital; Medicine/Oncology Bangkok, , Thailand, 10400
    • Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology Bangkok, , Thailand, 10700
  • Turkey,
    • Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi Edirne, , Turkey, 22030
    • Bezm-i Alem University Medical Faculty; Medical Oncology Istanbul, , Turkey, 34093
    • Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology Istanbul, , Turkey, 34300
    • Hacettepe Uni Medical Faculty Hospital; Oncology Dept Sıhhiye, Ankara, , Turkey, 06100
  • United Kingdom,
    • Barts & London School of Med; Medical Oncology London, , United Kingdom, EC1A 7BE
    • Royal Free Hospital; Oncology & Haematology London, , United Kingdom, NW3 2QG
    • St George's Hospital; Oncology London, , United Kingdom, SW17 0QT
    • Royal Marsden Hospital - London London, , United Kingdom, SW3 6JJ
    • Charing Cross Hospital; Medical Oncology. London, , United Kingdom, W6 8RF
    • Christie Hospital NHS Trust Manchester, , United Kingdom, M20 4BX
    • Nottingham City Hospital; Oncology Nottingham, , United Kingdom, NG5 1PB
    • Royal Marsden Hospital - Surrey Surrey, , United Kingdom, SM2 5PT
    • The Clatterbridge Cancer Centre NHS Foundation Trust Wirral, , United Kingdom, L63 4JY

Sponsors and Collaborators

Hoffmann-La Roche

More Information

No publications provided

Responsible Party: Sponsor
ClinicalTrials.gov Identifier: NCT03148418
Other Study ID Numbers: 2016-005189-75
Study First Received:
Last Updated:
Health Authority:

Additional relevant MeSH terms:

Atezolizumab

Antibodies, Monoclonal

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on May 30, 2019